Navigation Links
New Epidemiological Data Provide Additional Safety Evidence for Lantus®
Date:6/11/2012

PARIS, France, June 11, 2012 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) today announced new results of a large-scale epidemiological program, conducted by independent researchers in the northern European countries, at Kaiser Permanente in Northern and Southern California, and at the University of North Carolina in the United States, providing further evidence that there was no increased risk of cancer in people with diabetes treated with Lantus® (insulin glargine [rDNA origin] injection), compared to those treated with other insulins. These data were presented at the American Diabetes Association 72nd Scientific Sessions.

(Logo:  http://photos.prnewswire.com/prnh/20110624/NY25833LOGO )

Aiming to evaluate cancer risk in diabetes and generate comprehensive insulin glargine exposure data from large databases, the epidemiological program sponsored by Sanofi is the largest observational program designed for this purpose to date.

These new results reinforce the established safety profile of Lantus®, complementing the existing wealth of data already available(1) resulting from more than 80,000 patients enrolled in clinical trials and over 47 million patient-years(2) of treatment exposure to insulin glargine.

"Sanofi welcomes the results of the Northern European and United States epidemiological studies further supporting the safety of Lantus®," said Jean-Pierre Lehner, Senior Vice President, Chief Medical Officer, Sanofi. "These findings reassure healthcare professionals, people living with diabetes and their caregivers of the safety profile of Lantus®."

Northern European Database Study [American Diabetes Association 72nd Scientific Sessions Symposium CT-SY13]
This study is the largest of its kin
'/>"/>

SOURCE Sanofi
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. New Resource Provides Herb Industry With Sources of Quality Specifications
2. inVentiv Health Selected to Provide Sales Operations Support for Santarus
3. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
4. Generex Provides Update on Generex Oral-lyn™ Clinical & Regulatory Program
5. Health Diagnostic Laboratory, Inc. Provides Largest Corporate Gift in Science Museum of Virginias History
6. Generex Subsidiary Antigen Express Provides Update on AE37 Cancer Vaccines Clinical & Regulatory Strategy
7. Elsevier Acquires QUOSA, Provider of Life Sciences Content Management and Workflow Productivity Solutions
8. Oxford Finance Provides $15 Million Senior Secured Credit Facility to Private Equity Backed Healthcare Services Company
9. Insmed Incorporated Provides Corporate Update
10. Swiss, EMA, US Pharmacopoeia and World Health Organization Authorities to Provide an Update on Cool Chain Regulations
11. Van Andel Research Institute Study Provides New Details of Fundamental Cellular Process
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... , July 1, 2015   Decision ... frequently cited advantages of Otezla are its oral ... profile, as reported by surveyed rheumatologists. Otezla was ... for the treatment of active psoriatic arthritis in ... current standard of care includes conventional oral treatments ...
(Date:7/1/2015)... Bermuda , July 1, 2015  Axovant ... company focused on the treatment of dementia, today ... briefing on July 22 at 5:45 p.m. EDT ... the Alzheimer,s Association International Conference 2015 (AAIC). ... remarks: , Dr. Lawrence Friedhoff ...
(Date:7/1/2015)... ... 01, 2015 , ... Apex Therapeutics announced today that company CEO, David Broecker ... , The presentation took place on Tuesday, June 16 and provided an update ... APX3330 for the treatment of pancreatic cancer. A copy of the company overview ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... to take part in the first half of “Integrative Biotechnology,” an applied biotechnology ... established in summer 2014, this course combines students from both universities and is ...
Breaking Biology Technology:Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 3Apex Therapeutics Presented Company Overview at This Year’s BIO International Convention in Philadelphia, PA 2Rivier University and Beijing City University Academic and Cultural Exchanges Begin 2
... Net Income & EBITDA (as adjusted) Increases of 21% ... ... Mac-Gray Corporation,(NYSE: TUC ), the nation,s premier provider of laundry ... first quarter ended March 31, 2008., Mac-Gray reported record first-quarter revenue ...
... Dana-Farber and Colorado Treating Patients with ENMD-2076, ... Inc. (Nasdaq:,ENMD), a clinical-stage pharmaceutical company developing ... diseases, today announced that,Dana-Farber Cancer Institute has ... conducting a Phase 1 study of ENMD-2076 ...
... Wash., May 8 BioLife Solutions Inc.,(OTC Bulletin ... proprietary,hypothermic storage and cryopreservation media products for cells, ... for CryoStor,cryopreservation media has been accepted by the ... Chairman and Chief Executive Mike Rice commented: "We ...
Cached Biology Technology:Mac-Gray Corporation Announces First-Quarter 2008 Financial Results 2Mac-Gray Corporation Announces First-Quarter 2008 Financial Results 3Mac-Gray Corporation Announces First-Quarter 2008 Financial Results 4Mac-Gray Corporation Announces First-Quarter 2008 Financial Results 5Mac-Gray Corporation Announces First-Quarter 2008 Financial Results 6Mac-Gray Corporation Announces First-Quarter 2008 Financial Results 7Mac-Gray Corporation Announces First-Quarter 2008 Financial Results 8Mac-Gray Corporation Announces First-Quarter 2008 Financial Results 9Mac-Gray Corporation Announces First-Quarter 2008 Financial Results 10Mac-Gray Corporation Announces First-Quarter 2008 Financial Results 11Mac-Gray Corporation Announces First-Quarter 2008 Financial Results 12Mac-Gray Corporation Announces First-Quarter 2008 Financial Results 13Mac-Gray Corporation Announces First-Quarter 2008 Financial Results 14Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMed's Selective Kinase Inhibitor 2Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMed's Selective Kinase Inhibitor 3BioLife Solutions Announces FDA Master File Acceptance for CryoStor(TM) Pre-formulated Cryopreservation Media 2BioLife Solutions Announces FDA Master File Acceptance for CryoStor(TM) Pre-formulated Cryopreservation Media 3
(Date:6/30/2015)... , June 30, 2015 Genisphere ... as CEO to help further develop Genisphere,s therapeutics capabilities ... partnering experience, having spent much of the last 25 ... Amgen, Baxter Bioscience, and Johnson & Johnson. Tom started ... Technology and Biotech Corporate Finance. He graduated from Dartmouth ...
(Date:6/25/2015)... June 25, 2015  TAKE Solutions Ltd., a global ... the United States Patent and Trademark Office (USPTO) for ... leverages TAKE Solutions, Clinical Accelerators to reduce the time ... compared to standardization without the accelerators), thus reducing time ... At the heart of the patented Clinical ...
(Date:6/24/2015)... 2015 Biometry authentication provider KeyLemon today ... solution one face in. Logo ... face in, entering the expanding biometric authentication market ... biometric answer to the password problem. With advanced ... with KeyLemon, one face in allows users to ...
Breaking Biology News(10 mins):Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3TAKE Solutions Awarded Patent By USPTO 2KeyLemon Announces Partnership With Biometric Password Solution onefacein 2
... In the largest prospective study to date of children ... (ASD) compared to children without ASD, researchers found two ... the children with ASD. Published in the journal ... development, children who display early signs of ASD show ...
... A group of researchers in Israel, the United States and ... of "regenerative medicine," outlining for the first time connections ... and facial muscles. Some of these problems are surprisingly ... congenital heart defect. This basic research will provide a road ...
... Biking, running and walking are all good for you. But the ... from other joint problems or injuries. What to do? Just add ... found that people who used an immersible ergocycle basically an ... workout to using a typical stationary bike. "If you can,t ...
Cached Biology News:Distinct developmental patterns identified in children with autism during their first 3 years 2Distinct developmental patterns identified in children with autism during their first 3 years 3Researchers identify genetic basis of cardiac, craniofacial birth defects 2Researchers identify genetic basis of cardiac, craniofacial birth defects 3Everyone in the pool! Water workouts just as good as on land 2
... Form: buffered aqueous solution. ... from complex carbohydrates and glycoproteins. It is ... conditions where the pH must be neutral ... Unit Definition: One ...
... Finnpipette BioControl multichannel has ... as the single channel ... fits allseven multichannel and ... cone modules. Both pipettes ...
...
... to offer the ATTO-TAG series of ... primary amines. Developed by Novotny and ... reagents are similar to the important ... anthracene-2,3-dicarboxaldehyde, all of which are also ...
Biology Products: